GRAIL, Inc. (GRAL) shares surged 5.22% in pre-market trading on Monday, following a positive analyst update from Canaccord Genuity. The biotechnology company, known for its innovative cancer detection technologies, saw its stock price climb on the back of maintained confidence from Wall Street analysts.

Canaccord Genuity reaffirmed its Buy rating on GRAIL, signaling continued optimism about the company's prospects. In a notable move, the firm also raised its price target for GRAIL from $85 to $105, representing a significant 23.5% increase in their valuation of the company. This upward revision suggests that Canaccord Genuity sees substantial upside potential in GRAIL's stock.

The positive analyst action comes as GRAIL continues to make strides in the field of early cancer detection. While specific details of the analyst's reasoning were not provided, the maintained Buy rating and increased price target typically reflect confidence in a company's fundamentals, growth prospects, and market position. Investors appear to be reacting favorably to this vote of confidence, as evidenced by the pre-market stock movement.